Results 241 to 250 of about 34,514 (311)

Associations between Intraocular Pressure or Glaucoma Medication with Axial Length and Pathologic Myopia Incidence and Progression. [PDF]

Ophthalmol Sci
Wong MW, Li H, Dan YS, Lor SC, Soh R, Hoang QV, Chong RS.   +6 more
europepmc   +1 more source

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper, Daniel Ledwoń, Adam Sendecki, Patrycja Romaniszyn‐Kania, Aleksandra Tuszy, Julia Nycz, Andrzej W. Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas   +9 more
wiley   +1 more source

Diagnostic performance and generalizability of deep learning for multiple retinal diseases using bimodal imaging of fundus photography and optical coherence tomography. [PDF]

Front Cell Dev Biol
Gu X, Zhou Y, Zhao J, Zhang H, Pan X, Li B, Zhang B, Wang Y, Xia S, Lin H, Wang J, Ding D, Li X, Wu S, Yang J, Chen Y.   +15 more
europepmc   +1 more source

Changes in choroidal and retinal thickness 6 months before and during 18 months of orthokeratology lens treatment in myopic children

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate changes in choroidal and retinal thickness before and during myopia control treatment with orthokeratology lenses (OKL) in myopic children. Methods This was a sub‐study of CONTROL and CONTROL2 studies. The present study was a 2‐year, prospective, single‐group interventional study consisting of a 6‐month pre‐treatment ...
P. O. Hansen, F. Møller, T. M. Jakobsen
wiley   +1 more source

Predictive Factors for Macular Atrophy in Patients with Treated Myopic Macular Neovascularization. [PDF]

Clin Ophthalmol
Ferreira AM, Coelho-Costa I, Beato JN, Penas S, Rocha-Sousa A, Falcão M, Carneiro Â.   +6 more
europepmc   +1 more source

Aniridia‐associated keratopathy: Clinical and molecular mechanisms of disease progression and emerging therapeutic targets

Acta Ophthalmologica, EarlyView.
Abstract Congenital aniridia is a rare genetic disorder primarily caused by pathogenic variants of the PAX6 gene. It leads to various panocular anomalies, including aniridia‐associated keratopathy (AAK). This review highlights recent insights into its pathogenesis, focusing on clinical staging, microstructural changes in the cornea and molecular ...
N. Szentmáry, S. Suiwal, M. Amini, F. N. Fries, A. Náray, L. Latta, Z. Li, S. Li, S. Liu, S. L. Hsu, S. Kundu, G. Tóth, S. Trusen, J. Zimmermann, B. Seitz, B. Käsmann‐Kellner, Z. Hoxha, A. Langenbucher, O. Stachs, M. Cortón‐Perez, K. Tory, A. Csorba, Z. Z. Nagy, M. C. Acosta, J. Gallar, M. Csidey, E. Maka, T. Stachon   +27 more
wiley   +1 more source

Concerns regarding Palee et al. and reasserting the underlying mechanism of action in percutaneous tenotomy. [PDF]

Interv Pain Med
Sussman WI, Hall M, Boettcher BJ.
europepmc   +1 more source

Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline. Methods Medical records of 334 presumed cCSC patients were retrospectively reviewed.
Helena M. A. Feenstra, Tahir Cakar, Joost Brinks, Camiel J. F. Boon, Elon H. C. van Dijk   +4 more
wiley   +1 more source

Clinical spectrum and prevalence associations of chorioretinal damage in high myopia: a retrospective cross-sectional analysis. [PDF]

Front Med (Lausanne)
Li G, Wang Y, Chen X.
europepmc   +1 more source

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Acta Ophthalmologica, EarlyView.
Abstract Purpose Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC). Methods Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone.
Helena M. A. Feenstra, Issam El Mansori, Thomas J. van Rijssen, Roula Tsonaka, Roselie M. H. Diederen, Carel B. Hoyng, Reinier O. Schlingemann, Camiel J. F. Boon, Elon H. C. van Dijk   +8 more
wiley   +1 more source